DNSP-11

DNSP-11, short for dopamine neuron stimulating peptide-11, is a small synthetic peptide eleven amino acids long, carrying an amidated tail. It is derived not from the mature glial cell line-derived neurotrophic factor (GDNF) protein but from its proregion, the portion of the GDNF precursor that is cleaved away during processing; a post-translational processing model predicted that this proregion could yield smaller biologically active peptides, of which DNSP-11 is the best studied ^[1]. It was identified and characterized by Luke Bradley, Greg Gerhardt, and colleagues at the University of Kentucky's Parkinson's disease research center ^[1][2].

The scientific interest in DNSP-11 comes from the promise and the problems of GDNF. GDNF is one of the most potent known survival factors for the dopamine neurons that are lost in Parkinson's disease, but it is a large protein that diffuses poorly through brain tissue and is difficult to synthesize and modify. DNSP-11 was pursued as a much smaller molecule that reproduces GDNF-like neurotrophic actions while being easier to deliver and chemically alter ^[1]. Notably, it appears to act through a different route than GDNF, since it does not require the GFRalpha1 receptor that GDNF depends on ^[1].

Research to date is preclinical, spanning cell culture and rodent models of Parkinson's disease. Across these studies DNSP-11 has supported the survival of dopamine neurons, protected them from toxins, and enhanced dopamine-related function ^[1][2][3]. DNSP-11 is not an approved drug and is not a dietary supplement; it exists as a research peptide, typically supplied as a lyophilized powder, and is discussed within the neuroscience and longevity communities as an experimental neurotrophic agent aimed specifically at the dopamine system.

No human safety data of any kind exists. The entire repeated-dose tolerability record is one study (PMID 29614295): three treated and three vehicle rhesus macaques, all female, aged 10 to 18 years, intranasal for 10 weeks, reporting no epistaxis, no gastrointestinal irritation, no seizures or dyskinesia, no other observed behavioural effects, and body weight change of 5% or less. An n of 3 detects only gross toxicity and says nothing about uncommon or delayed harm.

Absent entirely: any published toxicology package, human pharmacokinetics, immunogenicity or anti-drug antibody testing, reproductive and carcinogenicity data, and drug interaction studies. Interactions are unknown rather than absent; because DNSP-11 measurably raises dopamine turnover in every species tested, a theoretical interaction with MAO inhibitors, levodopa, dopamine agonists and antipsychotics is mechanistically plausible but has never been examined.

Repeated intranasal dosing also carries the generic local risks of that route (mucosal irritation, epistaxis) which the primate study looked for but which no human has been assessed for. Regulatory status: not approved for human use by the FDA, the EMA or any other regulator, and not in any public clinical development pipeline. It is sold both as a laboratory reagent and by consumer-facing peptide vendors under research-use-only labelling; that labelling is a legal disclaimer, not a safety finding.

WADA: DNSP-11 is not named on the 2026 Prohibited List, but because no governmental regulatory health authority anywhere has approved it for human therapeutic use, it falls squarely within category S0 (Non-Approved Substances), which is prohibited at all times, in and out of competition. It is not a scheduled controlled substance in the United States.

DNSP-11 (dopamine neuron stimulating peptide-11) was identified and characterized by researchers at the University of Kentucky, in the laboratory group associated with Don M. Gash and colleagues who had long studied glial cell line-derived neurotrophic factor (GDNF) as a therapy for Parkinson's disease. The peptide is an 11-amino-acid sequence drawn from the pro-region of proGDNF, and it was pursued specifically because GDNF itself is a large protein that is difficult to deliver into the brain and hard to modify chemically.

The foundational report, published by Bradley and colleagues in PLoS ONE in 2010, described its ability to support fetal dopaminergic neuron survival in culture, to protect cells against the toxin 6-hydroxydopamine, and, after a single injection into the rat substantia nigra, to raise dopamine levels for as long as 28 days. Subsequent work examined its uptake into neurons and its capacity to enhance potassium-evoked dopamine release in specific striatal subregions. To date DNSP-11 remains an experimental research peptide; it has not advanced to approved clinical use, and its human pharmacology is not yet documented.

DNSP-11 is regarded within the neurotrophic-factor research community as an elegant proof of concept: that a very small fragment of proGDNF can reproduce meaningful features of the parent protein's dopamine-protective activity. What makes it compelling is the durability seen in preclinical models, where a single injection produced changes in dopamine chemistry lasting weeks rather than hours, alongside evidence of direct mitochondrial protection.

Researchers also note that it appears to act through a route that does not require the classical GFRalpha1 co-receptor, which is scientifically interesting for understanding how trophic signals can be delivered. Its appeal for those focused on dopaminergic health lies in this targeted, growth-factor-derived design. Honesty requires noting the limits, however: the evidence base is entirely preclinical, dosing and safety in humans are uncharacterized, and it should be understood as a research compound rather than an established intervention.